Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

(2011) G. Cancello et al.   BREAST CANCER RESEARCH AND TREATMENT

Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype

(2011) Rachel L. Theriault et al.   Clinical Breast Cancer

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis

(2011) Pietro Sanpaolo et al.   MEDICAL ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Implications of HER2 Amplification in Small, Node-Negative Breast Cancers: Do Asians Differ?

(2011) Fuh Yong Wong et al.   WORLD JOURNAL OF SURGERY

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

(2010) Ji Hyun Kwon et al.   BMC CANCER

HER2-neu Positivity Prognosticates for Poor Disease Control in Asian Women with Small, Node Negative Breast Cancer Treated with Conservation Therapy

(2010) F. Wong et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer

(2009) Michael Z. Gilcrease et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

(2009) Yeon Hee Park et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY